You are here

  • Home
  • Archive
  • Volume 81, Issue 10
  • Response to: ‘Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5 positive dermatomyositis associated rapidly progressive interstitial lung diseases: a challenge for the future’ by Wang et al

Article info

Article menu
Download PDFPDF
Correspondence response
Response to: ‘Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5 positive dermatomyositis associated rapidly progressive interstitial lung diseases: a challenge for the future’ by Wang et al

Authors

  • Janine A Lamb Division of Population Health, Health Services Research and Primary Care, The University of Manchester, Manchester, UK PubMed articlesGoogle scholar articles
  • Spyridon Megremis Division of Evolution and Genomic Sciences, The University of Manchester, Manchester, UK PubMed articlesGoogle scholar articles
  • Hector Chinoy National Institute for Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, The University of Manchester, Manchester, UK Department of Rheumatology, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Salford, UK PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Janine A Lamb, Division of Population Health, Health Services Research & Primary Care, The University of Manchester Faculty of Biology Medicine and Health, Manchester M13 9PT, UK; janine.lamb{at}manchester.ac.uk
View Full Text

Citation

Lamb JA, Megremis S, Chinoy H
Response to: ‘Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5 positive dermatomyositis associated rapidly progressive interstitial lung diseases: a challenge for the future’ by Wang et al
Annals of the Rheumatic Diseases 2022;81:e193.

Publication history

  • Received July 30, 2020
  • Accepted July 31, 2020
  • First published August 5, 2020.
Online issue publication 
October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage